BR112022025099A2 - Agente profilático ou terapêutico para porfiria - Google Patents

Agente profilático ou terapêutico para porfiria

Info

Publication number
BR112022025099A2
BR112022025099A2 BR112022025099A BR112022025099A BR112022025099A2 BR 112022025099 A2 BR112022025099 A2 BR 112022025099A2 BR 112022025099 A BR112022025099 A BR 112022025099A BR 112022025099 A BR112022025099 A BR 112022025099A BR 112022025099 A2 BR112022025099 A2 BR 112022025099A2
Authority
BR
Brazil
Prior art keywords
porphyria
pyrrolidin
prophylactic
therapeutic agent
cocrystal
Prior art date
Application number
BR112022025099A
Other languages
English (en)
Inventor
Suzuki Tsuyoshi
Kondo Masahiro
Takahashi Fumihiro
Ogasawara Akihito
Hyoudou Kazumi
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Priority claimed from PCT/JP2021/022036 external-priority patent/WO2021251450A1/ja
Publication of BR112022025099A2 publication Critical patent/BR112022025099A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

AGENTE PROFILÁTICO OU TERAPÊUTICO PARA PORFIRIA. Produto farmacêutico para tratamento ou prevenção de porfiria, compreendendo ácido 1-{2-[(3S,4R)-1-{[(3R,4R)-1-ciclopentil-3-fluor-4-(4-metoxifenil)pirrolidin-3-il]carbonil}-4-(metoximetil)pirrolidin-3-il]-5-(trifluormetil)fenil}piperidina-4-carboxílico ou um sal ou cocristal farmaceuticamente aceitável do mesmo como um ingrediente ativo, em que a dose do ácido 1-{2-[(3S,4R)-1-{[(3R,4R)-1-ciclopentil-3-fluor-4-(4-metoxifenil)pirrolidin-3-il]carbonil}-4-(metoximetil) pirrolidin-3-il]-5-(trifluormetil)fenil}piperidina-4-carboxílico ou do sal ou cocristal farmaceuticamente aceitável do mesmo é de 50 a 500 mg/dia.
BR112022025099A 2020-06-10 2021-06-10 Agente profilático ou terapêutico para porfiria BR112022025099A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020100952 2020-06-10
JP2020134451 2020-08-07
PCT/JP2021/022036 WO2021251450A1 (ja) 2020-06-10 2021-06-10 ポルフィリン症の予防又は治療剤

Publications (1)

Publication Number Publication Date
BR112022025099A2 true BR112022025099A2 (pt) 2023-02-14

Family

ID=78282128

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022025099A BR112022025099A2 (pt) 2020-06-10 2021-06-10 Agente profilático ou terapêutico para porfiria

Country Status (10)

Country Link
US (1) US20230248713A1 (pt)
EP (1) EP4166140A1 (pt)
JP (1) JP6959478B1 (pt)
KR (1) KR20230016006A (pt)
CN (1) CN115942934A (pt)
AU (1) AU2021289913B2 (pt)
BR (1) BR112022025099A2 (pt)
CA (1) CA3186880A1 (pt)
IL (1) IL298952A (pt)
MX (1) MX2022015804A (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024029599A1 (ja) * 2022-08-03 2024-02-08 田辺三菱製薬株式会社 １－｛２－［（３ｓ，４ｒ）－１－｛［（３ｒ，４ｒ）－１－シクロペンチル－３－フルオロ－４－（４－メトキシフェニル）ピロリジン－３－イル］カルボニル｝－４－（メトキシメチル）ピロリジン－３－イル］－５－（トリフルオロメチル）フェニル｝ピペリジン－４－カルボン酸もしくはその医薬的に許容し得る塩又は共結晶を含有する医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8334265B2 (en) 2006-08-31 2012-12-18 Clinuvel Pharmaceuticals Limited Method of treatment of photodermatoses
CN106458887B (zh) 2014-05-29 2020-10-30 田边三菱制药株式会社 吡咯烷化合物及作为黑皮质素受体激动剂的用途
TWI834791B (zh) 2018-12-28 2024-03-11 日商田邊三菱製藥股份有限公司 吡咯啶化合物的結晶

Also Published As

Publication number Publication date
JP6959478B1 (ja) 2021-11-02
KR20230016006A (ko) 2023-01-31
CN115942934A (zh) 2023-04-07
US20230248713A1 (en) 2023-08-10
JPWO2021251450A1 (pt) 2021-12-16
AU2021289913A1 (en) 2023-02-02
AU2021289913B2 (en) 2024-03-28
CA3186880A1 (en) 2021-12-16
MX2022015804A (es) 2023-04-05
IL298952A (en) 2023-02-01
EP4166140A1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX344308B (es) Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso.
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
RU2010107892A (ru) Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их
BR112012006010A2 (pt) composto de glicina
BR0311414A (pt) Agente terapêutico para uma bexiga hiperativa
NZ592615A (en) Method for treating or preventing thrombosis using 150 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
BRPI1014174B8 (pt) uso de um composto selecionado a partir de 4-((1s)-1-{[5-cloro-2-(4-fluorofenóxi)benzoil]amino}etil)ácido benzóico, 4-[(1s)-1-({[5-cloro-2-(3-fluorofenóxi)piridin-3-il]carbonil}amino)etil]ácido benzóico e 3-[2-(4-{2-etil-4,6-dimetil-1h-imidazo[4,5-c]piridin-1-il}fenil)etil]-1-[(4-metilbenzeno)sulfonil]urea para tratamento de um câncer epitelial relacionado à pge2
RU2012157328A (ru) Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера
RU2009144846A (ru) Использование модулятора рецептора s1p
MX2022015554A (es) Moduladores de molecula peque?a de interleucina 17 (il-17).
BR112022025099A2 (pt) Agente profilático ou terapêutico para porfiria
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
BR112012020060B8 (pt) uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
AR059838A1 (es) Formulaciones para dosis estabilizantes de estatina
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
JP6998881B2 (ja) 糖尿病性足感染症の処置のための医薬
AR122595A1 (es) Agente profiláctico o terapéutico para fotodermatosis
BR112012022944A2 (pt) agente terapêutico ou agente profilático
AR122591A1 (es) Agente profiláctico o terapéutico para porfirias
MD4802B1 (ro) Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor